
EBCC
26 interviews
European Breast Cancer Conference
Interviews and expert commentary from EBCC — study authors and key opinion leaders discuss the findings and their clinical implications.

Fleur Mauritz MD; EBCC 2026: RAPCHEM Study Shows Risk-Based Radiotherapy De-Escalation is Safe After Primary Systemic Therapy for Early Breast Cancer
Fleur Mauritz MD discusses the 10-year follow-up findings from the RAPCHEM study, presented at the EBCC 2026. The research indicates that risk-based radiotherapy de-escalation is safe and effective…

Jelle Wesseling MD PhD; 2026 EBCC: ‘Lord’ Trial Finds Active Surveillance for Estrogen-Receptor-Positive, HER2- Negative, Grade 1–2 DCIS Just As Effective as Standard Therapy
At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard…

Elisa Agostinetto MD; 2026 EBCC: Circulating Tumor DNA Trumps Clinical Prognostic Markers After Neoadjuvant Therapy for Patients with Early Breast Cancer
Elisa Agostinetto MD presented at EBCC 2026, highlighting circulating tumor DNA (ctDNA) as a superior prognostic marker over clinical indicators for predicting relapse and progression in early breast…

Kerstin Wimmer MD; 2026 EBCC: Polyurethane-Coated Implants Reduce Capsular Contracture Risk after Mastectomy with Radiotherapy for Breast Cancer
Kerstin Wimmer MD, at the 2026 EBCC, discussed the OPBC-09 PRExRT study findings, revealing that polyurethane-coated breast implants significantly reduce capsular contracture risk for breast cancer…

Fatima Cardoso MD; 2026 EBCC: OASIS-4 Trial Finds Elinzanetant Cuts Vasomotor Symptoms (“Hot Flashes”) in Endocrine Therapy-Treated Patients with Breast Cancer
At EBCC 2026, Fatima Cardoso MD discussed the OASIS-4 trial, revealing elinzanetant greatly reduced vasomotor symptoms ("hot flashes") in breast cancer patients receiving endocrine therapy. This dual…

Elisabetta Bonzano MD PhD; 2025 EBCC: BRAVE-HEART Study Shows How Breath-Holding System Halves Coronary Radiation Dose During Left Breast Irradiation
Elisabetta Bonzano MD PhD discusses the BRAVE-HEART study at the 2025 EBCC, revealing how the Active Breathing Co-ordination (ABC) system significantly halves the coronary radiation dose during left…

Philip Poortmans MD PhD; 2026 EBCC: European Breast Cancer Conference: Focus on Therapy De-escalation and Individualization
This episode features Philip Poortmans MD PhD, University of Antwerp & Iridium Netwerk, discussing key themes from the 2026 European Breast Cancer Conference. He focuses on individualizing breast…

Tess Snellen MD; 2026 EBCC: Molecular Test Distinguishes Ipsilateral Second Primary from Recurrent Breast Cancer
Tess Snellen MD, from the Netherlands Cancer Institute, presents key findings at the EBCC 2026 regarding a molecular test. This innovative test utilizes next-generation sequencing to precisely…

Heather McArthur MD MPH: Adjuvant Checkpoint Inhibition: Did Not Improve Survival in Patients with Triple-Negative Breast Cancer
Heather McArthur MD MPH

Stefan Paepke MD: An End to “Jumping Breasts” with Mesh Supported Pre-Pectoral Breast Implants
Stefan Paepke MD

Sophie Bosma MD PhD:“Young Boost” Trial Finds Low-Dose Radiation Boost Optimal for Young Patients with High-Risk Early Breast Cancer
Sophie Bosma MD PhD

Adri Voogd PhD: Ductal Carcinoma in Situ: Good Outcomes from Breast Conserving Therapy, but Benefits, Risks, Costs Still Need to be Optimized
Adri Voogd PhD

Annemiek van Hemert MD PhD: “Breast Cancer: MARI Node Marker Helps Most Patients with Extensive Nodal Disease Safely Avoid Axillary Lymph Node Dissection”
Annemiek van Hemert MD PhD

Tim Rattay MBChB PhD: Artificial Intelligence Tool Minimizes Arm Lymphedema After Breast Cancer Surgery and Radiotherapy
Tim Rattay MBChB PhD

Yasmin Civil MD PhD: Low-Risk ER+ Breast Cancer: ABLATIVE Trial Finds Marked Benefit from MRI-Guided Single-Dose Neoadjuvant Partial Breast Radiotherapy
Partial breast irradiation, given before breast-conserving surgery, achieved durable pathologic complete remissions in low-risk breast cancer, and even held out the prospect of surgery-free treatment

Neo-Adjuvant Pembrolizumab Improved Outcomes with High-Risk ER+ HER2- Early Breast Cancer
Heather McArthur MD MPH

Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab
ImPrintTN single-sample classifier identifies no benefit from deoadjuvant pembroliozumab in TNBC

Breast Lumps Between Mammography Visits Signal High Risk
BARCELONA—Women who develop breast symptoms—especially lumps—between regular mammography screening examinations are up to four times more likely to have a diagnosis of breast cancer soon after than wo

Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer
BARCELONA—More pre-menopausal women who have estrogen receptor (ER) positive advanced breast cancer could be spared chemotherapy—according to latest findings from the MONALEESA-7 double-blind randomiz

Reassurance on Ductal Carcinoma in Situ (DCIS) Treatment De-Escalation
BARCELONA—A multicenter nationwide Italian study of patients with ductal carcinoma in situ (DCIS) treated with breast conservative surgery (BCS) and whole breast radiotherapy (RT) has updated risk cri